Lauterbach rejects concerns over influenza vaccine shortages as deliveries catch up

0:00

(de-news.net) – Despite delivery delays and reported shortages in medical practices, former Federal Health Minister Karl Lauterbach (SPD) has dismissed worries about a national influenza vaccine shortage, arguing that Germany’s supply of 20 million doses is adequate. While general practitioners continue to report local distribution issues, health authorities have confirmed that vaccine approvals have caught up to previous years’ levels. In an independent development, Techniker Krankenkasse anticipates keeping its additional contribution rate in 2027, despite ongoing cautions that more reforms might be required to stop increases in health insurance contributions starting in 2028.

Lauterbach has sought to reassure the public that Germany has sufficient influenza vaccine supplies despite reports of delayed deliveries and shortages in general practitioners’ offices. According to Lauterbach, approximately 20 million doses have been ordered and are expected to be delivered. He attributed the distribution delays to the need to adapt vaccines for the current influenza season, arguing that their late availability reflected the timing of vaccine development rather than political or administrative shortcomings.

Lauterbach urges older people to arrange vaccinations

Lauterbach emphasized that the influenza season generally gathers momentum around Christmas and continues into January, meaning that sufficient time remains for people to receive their vaccinations. He particularly urged individuals over 60 and younger people with underlying health conditions or other risk factors to arrange appointments with general practitioners or pharmacies without delay. If a preferred vaccine is unavailable, patients could use an alternative, he said, maintaining that all available vaccines offered high levels of protection.

Highlighting the potential consequences of influenza infections, Lauterbach cited approximately 16,000 deaths during the previous season and argued that vaccination could have prevented many of them. He also pointed to the risk of serious cardiovascular complications, including heart attacks and strokes, which can occur following influenza infections. Studies indicate that influenza vaccination has an average effectiveness of approximately 41 percent among older adults.

General practitioners report delivery problems

Lauterbach’s reassurances followed complaints from Nicola Buhlinger-Göpfarth, chairwoman of the German Association of General Practitioners and Family Physicians, who reported that numerous medical practices had received influenza vaccines considerably later than expected or in quantities below those ordered. The resulting supply difficulties had forced some doctors to contact multiple pharmacies to locate additional doses, while scheduled vaccinations were being postponed.

Buhlinger-Göpfarth warned that these disruptions were directly affecting the vaccination campaign at a time when immunization rates were already insufficient. The difficulties have been linked to delays in vaccine production and the testing and release of individual batches by the Paul Ehrlich Institute (PEI). A spokesperson for the institute confirmed that testing and approval procedures had begun later this year than in previous seasons but rejected concerns about a nationwide supply shortage.

According to the PEI’s latest figures, approximately 20.2 million doses had been approved for distribution, bringing the number of released vaccines back to levels recorded in previous years. The Federal Association of German Pharmacists’ Associations also maintained that the overall supply situation remained secure, despite occasional shortages at individual locations.

Health authorities emphasize timely immunization

The Robert Koch Institute recommends annual influenza vaccination between October and mid-December to allow sufficient time for immunity to develop before the seasonal wave generally reaches its peak after the turn of the year. Its recommendations cover people aged 60 and older, individuals with chronic illnesses, pregnant women, residents of nursing and care facilities, medical personnel, and other groups at increased risk of complications.

Similar supply difficulties occurred during the previous influenza season, when relatively strong demand and an early outbreak contributed to shortages in some general practitioners’ offices by mid-December. One structural challenge is that medical practices must order vaccines approximately nine months in advance, when actual demand is often difficult to predict. Ordering excessive quantities also carries financial risks because health insurers can impose penalties on practices purchasing more doses than they ultimately require.

Techniker Krankenkasse expects stable contribution rate

Separately, Jens Baas, Chief Executive of Techniker Krankenkasse (TK), said the insurer intended to maintain its additional contribution rate at 2.69 percent next year. However, he cautioned that statutory health insurers could still be forced to increase their rates during the year if the savings anticipated under the Government’s reform package proved smaller than expected. He also warned that the planned measures would not be sufficient to prevent contribution increases in 2028 without further reforms.

Federal Health Minister Carsten Linnemann (CDU) had previously indicated in mid-October that the average additional contribution rate for statutory health insurance could remain stable in 2027. His assessment was based on financial projections from the official estimates group of the statutory health insurance system. Linnemann attributed the expected stabilization primarily to the statutory health insurance contribution stabilization law, which is projected to reduce insurers’ expenditure by up to 15 billion euros next year.

Leave a Reply

Your email address will not be published. Required fields are marked *